Hisamitsu Pharmaceutical Toekomstige groei

Future criteriumcontroles 2/6

Hisamitsu Pharmaceutical zal naar verwachting groeien in winst en omzet met respectievelijk 11.1% en 3.7% per jaar. De winst per aandeel zal naar verwachting groeien met 14% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 7.3% zijn.

Belangrijke informatie

11.1%

Groei van de winst

14.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	11.7%
Inkomstengroei	3.7%
Toekomstig rendement op eigen vermogen	7.3%
Dekking van analisten	Low
Laatst bijgewerkt	22 Oct 2024

Recente toekomstige groei-updates

Recent updates

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Nov 08

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Nov 04

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Oct 17

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Sep 16

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 20

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

Jul 26

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Jul 11

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Jun 13

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Apr 09

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Mar 18

Winst- en omzetgroeiprognoses

TSE:4530 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
2/28/2027	165,000	19,200	23,427	N/A	1
2/28/2026	157,500	15,900	19,818	N/A	1
2/28/2025	154,500	17,200	5,208	N/A	1
8/31/2024	150,185	14,650	176	18,593	N/A
5/31/2024	145,420	14,708	N/A	N/A	N/A
2/29/2024	141,706	13,969	5,152	18,188	N/A
11/30/2023	139,276	14,330	N/A	N/A	N/A
8/31/2023	135,688	13,655	2,186	12,416	N/A
5/31/2023	134,033	14,160	N/A	N/A	N/A
2/28/2023	128,330	11,742	4,819	12,727	N/A
11/30/2022	125,411	12,962	N/A	N/A	N/A
8/31/2022	121,261	11,160	8,832	12,698	N/A
5/31/2022	118,825	8,927	N/A	N/A	N/A
2/28/2022	120,193	9,658	15,006	19,199	N/A
11/30/2021	120,351	9,746	N/A	N/A	N/A
8/31/2021	120,135	10,559	12,153	15,796	N/A
5/31/2021	117,389	11,499	N/A	N/A	N/A
2/28/2021	114,510	9,250	1,901	5,289	N/A
11/30/2020	122,736	8,996	N/A	N/A	N/A
8/31/2020	130,517	14,839	19,468	23,638	N/A
5/31/2020	136,641	16,894	N/A	N/A	N/A
2/29/2020	140,992	18,694	23,669	27,395	N/A
11/30/2019	139,912	21,295	N/A	N/A	N/A
8/31/2019	137,425	17,594	12,616	16,497	N/A
5/31/2019	139,142	17,665	N/A	N/A	N/A
2/28/2019	143,408	19,204	12,109	15,772	N/A
11/30/2018	140,891	16,608	N/A	N/A	N/A
8/31/2018	143,791	18,891	18,299	21,587	N/A
5/31/2018	145,288	18,897	N/A	N/A	N/A
2/28/2018	147,870	19,119	N/A	30,453	N/A
11/30/2017	145,749	17,895	N/A	N/A	N/A
8/31/2017	144,941	20,495	N/A	25,077	N/A
5/31/2017	143,853	19,540	N/A	N/A	N/A
2/28/2017	145,925	20,395	N/A	19,910	N/A
11/30/2016	149,298	20,806	N/A	N/A	N/A
8/31/2016	153,871	17,694	N/A	27,819	N/A
5/31/2016	160,325	18,778	N/A	N/A	N/A
2/29/2016	161,852	17,784	N/A	30,923	N/A
11/30/2015	164,086	19,626	N/A	N/A	N/A
8/31/2015	162,119	18,586	N/A	25,757	N/A
5/31/2015	158,667	18,321	N/A	N/A	N/A
2/28/2015	156,743	18,784	N/A	23,232	N/A
11/30/2014	150,446	16,645	N/A	N/A	N/A
8/31/2014	150,305	17,250	N/A	29,649	N/A
5/31/2014	151,326	17,841	N/A	N/A	N/A
2/28/2014	150,635	21,357	N/A	35,845	N/A
11/30/2013	150,544	22,976	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 4530 ( 11.1% per jaar) ligt boven de spaarquote ( 0.3% ).

Winst versus markt: De winst van 4530 ( 11.1% per jaar) zal naar verwachting sneller groeien dan de JP markt ( 7.9% per jaar).

Hoge groeiwinsten: De winst van 4530 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 4530 ( 3.7% per jaar) zal naar verwachting langzamer groeien dan de markt JP ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van 4530 ( 3.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 4530 zal naar verwachting over 3 jaar laag zijn ( 7.3 %).

Hisamitsu Pharmaceutical Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 15% to JP¥4,250

Price target increased by 16% to JP¥4,450

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023

Price target increased to JP¥3,700

Price target increased to JP¥3,700

Recent updates

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

First half dividend of JP¥45.00 announced

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Upcoming dividend of JP¥45.00 per share

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024

Upcoming dividend of JP¥42.50 per share

Price target decreased by 15% to JP¥4,250

Third quarter 2024 earnings released: EPS: JP¥48.25 (vs JP¥37.89 in 3Q 2023)

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2024 Results on Jan 11, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥42.50 per share at 1.8% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2024 Results on Oct 06, 2023

Price target increased by 16% to JP¥4,450

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.57% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024

Full year 2023 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2024 Results on Jul 13, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥42.25 per share at 2.1% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2023 Results on Apr 13, 2023

Third quarter 2023 earnings released: EPS: JP¥37.89 (vs JP¥14.91 in 3Q 2022)

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023

Price target increased to JP¥3,700

Less than half of directors are independent

Price target increased to JP¥3,700

Consensus forecasts updated

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2023 Results on Jan 12, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.51% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter Ended August 31, 2022, Payable on Nov. 9, 2022; Provides Dividend Guidance for the full year ending February 28, 2023

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2023 Results on Oct 12, 2022

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter and Full Year Ending February 28, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2023 Results on Jul 07, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2023

Upcoming dividend of JP¥42.00 per share

Upcoming dividend of JP¥42.00 per share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2022 Results on Apr 07, 2022

Consensus EPS estimates fall by 19%

Price target decreased to JP¥3,600

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2022

Second quarter 2022 earnings released: EPS JP¥32.30 (vs JP¥43.82 in 2Q 2021)

Upcoming dividend of JP¥42.00 per share

First quarter 2022 earnings released: EPS JP¥28.90 (vs JP¥1.38 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥113 (vs JP¥228 in FY 2020)